Shopping Cart 0
Cart Subtotal
USD 0

Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 11 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 1 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H7N9 Subtype Infections-Overview

Influenza A Virus, H7N9 Subtype Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H7N9 Subtype Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H7N9 Subtype Infections-Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Cocrystal Pharma Inc

EpiVax Inc

Fabentech SA

Genentech Inc

GlaxoSmithKline Plc

iBio Inc

Inovio Pharmaceuticals Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Nanotherapeutics Inc

NanoViricides Inc

NewLink Genetics Corp

Novavax Inc

Sanofi Pasteur SA

Visterra Inc

Vivaldi Biosciences Inc

Influenza A Virus, H7N9 Subtype Infections-Drug Profiles

AT-501-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-42344-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FBF-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3206640A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (virus like particle, monovalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-295-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-1851-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neuraminidase A for Infectious Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H7N9 Subtype Infections-Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Cocrystal Pharma Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by EpiVax Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Fabentech SA, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Genentech Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by GlaxoSmithKline Plc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by iBio Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Medicago Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Medigen Vaccine Biologics Corp, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Nanotherapeutics Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by NanoViricides Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by NewLink Genetics Corp, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Novavax Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Sanofi Pasteur SA, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Visterra Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Vivaldi Biosciences Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Dormant Projects, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Influenza A Virus, H7N9 Subtype Infections Therapeutic Products under Development, Key Players in Influenza A Virus, H7N9 Subtype Infections Therapeutics, Influenza A Virus, H7N9 Subtype Infections Pipeline Overview, Influenza A Virus, H7N9 Subtype Infections Pipeline, Influenza A Virus, H7N9 Subtype Infections Pipeline Assessment


Companies

Beijing Minhai Biotechnology Co Ltd

Cocrystal Pharma Inc

EpiVax Inc

Fabentech SA

Genentech Inc

GlaxoSmithKline Plc

iBio Inc

Inovio Pharmaceuticals Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Nanotherapeutics Inc

NanoViricides Inc

NewLink Genetics Corp

Novavax Inc

Sanofi Pasteur SA

Visterra Inc

Vivaldi Biosciences Inc

Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 11 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 1 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H7N9 Subtype Infections-Overview

Influenza A Virus, H7N9 Subtype Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H7N9 Subtype Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H7N9 Subtype Infections-Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Cocrystal Pharma Inc

EpiVax Inc

Fabentech SA

Genentech Inc

GlaxoSmithKline Plc

iBio Inc

Inovio Pharmaceuticals Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Nanotherapeutics Inc

NanoViricides Inc

NewLink Genetics Corp

Novavax Inc

Sanofi Pasteur SA

Visterra Inc

Vivaldi Biosciences Inc

Influenza A Virus, H7N9 Subtype Infections-Drug Profiles

AT-501-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-42344-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FBF-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3206640A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (virus like particle, monovalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-295-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-1851-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neuraminidase A for Infectious Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H7N9 Subtype Infections-Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Cocrystal Pharma Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by EpiVax Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Fabentech SA, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Genentech Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by GlaxoSmithKline Plc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by iBio Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Medicago Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Medigen Vaccine Biologics Corp, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Nanotherapeutics Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by NanoViricides Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by NewLink Genetics Corp, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Novavax Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Sanofi Pasteur SA, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Visterra Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Vivaldi Biosciences Inc, H1 2017

Influenza A Virus, H7N9 Subtype Infections-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Influenza A Virus, H7N9 Subtype Infections Therapeutic Products under Development, Key Players in Influenza A Virus, H7N9 Subtype Infections Therapeutics, Influenza A Virus, H7N9 Subtype Infections Pipeline Overview, Influenza A Virus, H7N9 Subtype Infections Pipeline, Influenza A Virus, H7N9 Subtype Infections Pipeline Assessment


Companies

Beijing Minhai Biotechnology Co Ltd

Cocrystal Pharma Inc

EpiVax Inc

Fabentech SA

Genentech Inc

GlaxoSmithKline Plc

iBio Inc

Inovio Pharmaceuticals Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Nanotherapeutics Inc

NanoViricides Inc

NewLink Genetics Corp

Novavax Inc

Sanofi Pasteur SA

Visterra Inc

Vivaldi Biosciences Inc